Oncologists, Rheumatologists Warn HHS Not To Move Part B Drugs Into Part D

Specialists with a big stake in Part B warn HHS that following through with the administration’s proposal to let Part D plans negotiate Part B drug prices would cause patients to face access restrictions in Part D that they don’t have to deal with in Part B. Also, rheumatologists say rheumatoid arthritis drugs listed on the drug spending dashboard are cheaper in Part B than in Part D. Despite strong opposition from both brand drug makers and specialists, HHS Secretary...